Latest Asx Company Filings News

Magontec Limited reported a net loss of $5.4 million for 2025 on a 10.9% drop in revenue, yet net tangible assets per share rose significantly to 76 cents.

Bapcor Limited has postponed its half-year financial results release to no later than 27 February 2026 and is seeking an extension of its trading suspension, hinting at a potential capital raising.

Wagners Holding Company Limited has reported a robust half-year result for December 2025, with revenue climbing to $251.7 million and net profit after tax soaring 70% to $21 million. Improved margins and operational efficiencies across key segments underpin the strong performance.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

Thorney Technologies reported a sharply reduced half-year profit amid challenging market conditions but extended its share buyback to support shareholder value.

Orcoda Limited has reported strong half-year FY26 results, showcasing significant growth in revenue, EBITDA, and recurring revenue as it advances its AI-powered transport ecosystem solutions.

Foresta Group Holdings reported a 12% increase in its half-year loss to nearly $2 million as it progresses its pioneering wood pellet and pine chemicals project in New Zealand, securing key lease agreements and finalising a $2.4 million insurance settlement.

CVC Limited posted a $6.7 million net loss for the half-year ended December 2025, driven by project delays and absent property sales, while strengthening liquidity through refinancing.

K&S Corporation’s half-year results reveal a notable decline in revenue and net profit, accompanied by a reduced interim dividend, signaling challenges ahead for the logistics firm.

Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

Kelsian Group Limited has reported a robust first half for FY26 with double-digit revenue growth and upgraded EBITDA guidance, alongside a strategic $161 million sale of its Tourism Portfolio.